Extended Data Fig. 10: Clinical vignettes of patients with HRD tumours.

a, Patient with BRCA2d neuroendocrine prostate cancer. Top left, prostate-specific antigen (PSA) and carcinoembryonic antigen (CEA) response kinetics. Time points 1–4 correspond to axial computed tomography images depicted on bottom right, illustrating favourable response to platinum-based chemotherapy. Right, classifier scores (top) and genomic features (bottom) for the highlighted patient (vertical lines) vs dataset-wide distributions stratified by genotype (violin plots; BRCA1d n = 102, BRCA2d n = 158, HRP n = 4360, HRP). b, Metastatic pancreas adenocarcinoma case with high B1 score (0.962), with CA19-9 response kinetics (left) and serial axial computed tomography (CT) (blue triangles and corresponding right panels) demonstrating excellent response to chemotherapy. c, High risk stage IIb pancreas adenocarcinoma case (WCM1462) with high B2 score (0.31), with CA19-9 and CEA response kinetics (top) and axial CT (bottom). LOH = burden of large genomic segments harbouring loss of heterozygosity. ihDels = count of large deletions (>1 kbp) with homeology. mhDel proportion = proportion of small deletions (<50 bp) with microhomology. RS3, RS5 = proportion of junctions with rearrangement signature 3 or 5 (ref. ²). SBS3, SBS8: COSMIC single base signature 3 and 8 (ref. ⁶⁰).